These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21113620)

  • 1. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
    Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
    Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
    Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
    Son HS; Lee WY; Lee WS; Yun SH; Chun HK
    Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
    J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of capecitabine-induced hand-foot syndrome by local phytotherapy].
    Kern E; Schmidinger M; Locker GJ; Kopp B
    Wien Med Wochenschr; 2007; 157(13-14):337-42. PubMed ID: 17704983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of hand foot syndrome with capecitabine.
    Kamil M; Haron M; Yosuff N; Khalid I; Azman N
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):421-2. PubMed ID: 20642979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
    Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
    Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
    Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
    Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.
    Wolf SL; Qin R; Menon SP; Rowland KM; Thomas S; Delaune R; Christian D; Pajon ER; Satele DV; Berenberg JL; Loprinzi CL;
    J Clin Oncol; 2010 Dec; 28(35):5182-7. PubMed ID: 21060036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
    Lu GC; Fang F; Li DC
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):152-5. PubMed ID: 20403249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and hand-foot syndrome.
    Saif MW
    Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
    Saif MW; Sandoval A
    Cutan Ocul Toxicol; 2008; 27(4):311-5. PubMed ID: 19037763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
    Vickers MM; Easaw JC
    J Gastrointest Cancer; 2008; 39(1-4):141-3. PubMed ID: 19440857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Lin E; Morris JS; Ayers GD
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):31-7. PubMed ID: 12520638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
    Saif MW; Elfiky A; Diasio R
    Clin Colorectal Cancer; 2006 Sep; 6(3):219-23. PubMed ID: 17026792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hand-foot syndrome with capecitabine therapy].
    Marini A; Hengge UR
    Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acral and palmo-plantar hyperpigmentation in a patient with disseminated hepatocellular carcinoma.
    Goyal R; Chalamalasetty SB; Madan K; Paul SB; Arora R; Safaya R; Acharya SK
    Indian J Gastroenterol; 2007; 26(6):292-3. PubMed ID: 18431015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.